Law Firm Probes Catalyst Pharmaceuticals’ $31.50-Per-Share Sale to Angelini Pharma
Halper Sadeh LLC is investigating Catalyst Pharmaceuticals’ $31.50-per-share sale to Angelini Pharma for potential securities law violations and breaches of fiduciary duty. The firm warns insiders may receive preferential benefits and urges shareholders to explore legal options at no upfront cost.
1. Investigation Overview
Halper Sadeh LLC has launched an inquiry into Catalyst Pharmaceuticals’ sale to Angelini Pharma, examining potential breaches of fiduciary duty and violations of federal securities laws.
2. Sale Terms
Under the proposed agreement, shareholders would receive $31.50 in cash for each Catalyst share upon closing of the transaction.
3. Potential Concerns
The firm highlights that certain transaction terms may limit competing bids and that insiders could secure financial perks not extended to ordinary shareholders.
4. Shareholder Actions
Catalyst investors are encouraged to contact Halper Sadeh LLC to discuss their rights and options on a contingent fee basis, with no upfront legal fees.